Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2024-06-05 00:00:00 ET · period of report 2024-06-03 · accession 0000875320-24-000168 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-06-05 | 2024-06-03 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $460.00 | -2,175 | 49.1K | -4% | -$1.00M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-06-03 | S | D | 2,175 | $460.00 | 49,098 | D | — | — |